Eisai’s Embolic Beads For Hepatocellular Carcinoma Approved In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai received manufacturing and marketing approval in Japan for its DC Bead used in transcatheter arterial embolization in patients with hepatocellular carcinoma, the company announced April 17.